학술논문
Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial.
Document Type
Article
Author
Source
Subject
*AMINOGLYCOSIDES
*GRAM-negative bacterial diseases
*KIDNEY injuries
*ATORVASTATIN
*APACHE (Disease classification system)
*BIOMARKERS
*CHI-squared test
*CREATININE
*CLINICAL drug trials
*FISHER exact test
*NEUTROPHILS
*PLACEBOS
*PILOT projects
*RANDOMIZED controlled trials
*CONTROL groups
*ACUTE diseases
*DATA analysis software
*DESCRIPTIVE statistics
*BLOOD urea nitrogen
*AMIKACIN
*BACTERIAL disease treatment
*THERAPEUTICS
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1735-1995
Abstract
Background: The most common clinical indication of aminoglycosides (AG) is the treatment of serious Gram-negative infections. The aim of this study was to evaluate plausible effects of atorvastatin on the biomarkers of acute kidney injury (AKI) in patients receiving amikacin. Materials and Methods: In this double-blinded randomized clinical trial, fifty patients (25 in each group) receiving amikacin (15 mg/kg/day) were randomly assigned to either atorvastatin (40 mg/day) or placebo (40 mg/day) groups for 7 days. Blood urea nitrogen (BUN), serum creatinine (SCr), and urinary neutrophil gelatinase-associated lipocalin (NGAL) levels were measured at days 0, 1, and 7 of amikacin treatment. Results: During the study period, 4 (8%) patients including two patients in each atorvastatin and placebo group experienced AKI. Urine NGAL/urine Cr did not change significantly between and within placebo and atorvastatin groups during the study period. Similarly, the mean changes in SCr, BUN, and urine NGAL/urine Cr values did not differ significantly between and within patients with and without AKI. Conclusion: Our data suggested that the changing pattern of urine NGAL/urine Cr ratio did not differ significantly between the atorvastatin and placebo groups during the early phase of amikacin treatment. [ABSTRACT FROM AUTHOR]